Skip to main content

Table 3 One way s ensitivity analysis

From: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

  Arm A Arm B ICER B/A
  Costs € / utility Costs €/ utility €/QALY
Base case 27 734 €/0.51 31 688 €/ 0.52 395400
Utility of patients treated by erlotinib    
−20% (0.538) 27 734 €/ 0.48 31 688 €/ 0.51 131800
−10% (0.606) 27 734 €/0.51 31 688 €/ 0.52 395400
+10% (0.740) 27 734 €/ 0.54 31 688 €/ 0.54 NA
+20% (0.807) 27 734 €/ 0.57 31 688 €/ 0.55 NA
Post-progression cost    
1627 € 25 954 €/ 0.51 28 787 €/ 0.52 283300
3021 € 29 514 €/ 0.51 34 588 €/ 0.52 507400
Erlotinib tariff    
−30% 24 282 €/ 0.51 29 788 €/ 0.52 550600
+ 30% 31 186 €/ 0.51 33 588 €/ 0.52 240200
  1. Arm A: erlotinib followed by docetaxel and gemcitabine (DG); Arm B: DG followed by erlotinib.